BioWorld

July 28, 2003

Fourth Approval For Enbrel: Amgen Adds Spinal Arthritis

As expected, Amgen Inc. and Wyeth Pharmaceuticals won marketing clearance from the FDA for Enbrel (etanercept) against ankylosing spondylitis, or arthritis of the spine. (BioWorld Today) Read More

Vertex Still Expects Approval Of 908 Despite Missed Main Endpoint

Pain Perception Arises In Remote Region Of Brain's Cerebral Cortex; Gene Therapy Trial Back-Burnered

House Passes Bill That Would Allow Reimportation Of Drugs

Chiron Sells $450M In Notes To Replenish Cash Position

Roche Secures Rights To Origen Via $1.4B Purchase From IGEN

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...